Friday, September 30, 2016 9:08:41 PM
>>there has been one local case of transmission confirmed in Utah. How it passed from father to son in that case was a mystery, but in the New England Journal of Medicine, researchers now say it likely passed through sweat or tears. That would make it the first case transmitted in that manner. The father, who eventually died from the disease -- the only American case to do so -- had a virus level 100,000 times higher than typical Zika patients.<<
Too bad that they didn't both either have a visionary Doctor or likely the time frame available to get this father authorized to be hooked up to the Aethlon hemopurifier as Dr Michael Mawanda, who was saved from ebola death was. This is exactly Why? this next broad spectrum experimental approval of the Aethlon Hemopurifier is so crucial and critical.
Dr. Mawanda’s miraculous recovery from Ebola:
http://www.newvision.co.ug/new_vision/news/1316079/dr-mawanda-miraculous-recovery-ebola
But then again, the Zika virus, according to our resident "SH" expert, is reported to be all "blowing over" and not really a problem at all anymore as he has also reported are all the other "inconvenient" viral pathogens that are constantly constantly popping up and morphing away from the testing of conventional treatment protocols and killing people. According to his previously referenced "experts" Five years is about the average time frame from viral birth to it's natural demise.
So What's the big deal? What's that to Worry about??
The Black Death or Black Plague was one of the most devastating pandemics in human history, resulted in the deaths of an estimated 75 to 200 million people and peaked in Europe in the years 1346–53. (Which is 7 years and at a time when the World population and contagion possibilities, due to travel, were a mere fraction of what they are Today.)
https://en.wikipedia.org/wiki/Black_Death
So sad that this Aethlon and JJ hater doesn't have the capabilities or the compassion to understand the realities of this situation and that regardless of anything; The Aethon Hemopurifier must continue on to prove itself. Billions are being spent chasing down the illusive individual and constantly changing viral strain when the embedded lectin and hemopurifier process might be able to capture much of the whole crowd... That's what the continuous testing is all about.
Best weekend to all and RIP to another medical visionary, Dr. Dale B. Schenk
dp
Re: AVE ATQUE VALE DALE SCHENK
Oh my... Seems so sudden to his "medical leave" announcement.
God Bless him for all the people he devoted his life in trying to Help. The World just lost a great humanitarian and medical visionary whose works will continue on to benefit many.
King James Bible - 2 Timothy 4:7
I have fought a good fight, I have finished my course, I have kept the faith:
Rest in Peace Dale. You have finished your course well....
In Memoriam - Friend, Scientific Innovator and Leader Dr. Dale B. Schenk has Passed Away
GlobeNewswire•September 30, 2016
DUBLIN, Ireland, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), announced today that its Co-founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away this morning, after confronting his pancreatic cancer with the same courage, determination and humor that pervaded all areas of his life.
"Dale was a dear friend and colleague, and the broader scientific community has lost an incredibly innovative and creative leader," stated Lars G. Ekman, MD, PhD, Chairman of the Prothena Board of Directors. "Dale will be remembered not only for his pioneering work in protein immunotherapy that laid the foundation for many of today`s most promising therapeutic approaches, but also as a courageous scientist and business leader with a terrific sense of humor. His infinite energy and passion for applying scientific discoveries toward the development of new medicines for untreatable diseases leaves a lasting legacy to science and patients, and will continue to inspire us. On behalf of the Board of Directors, Prothena management team and employees, we deeply mourn his loss and extend our sympathies to his family."
The Board is meeting shortly regarding succession and an announcement will follow.
Dr. Schenk began his career as a researcher and pioneered the immunotherapeutic approach for the treatment of protein misfolding diseases, as exemplified by Alzheimer`s disease; his groundbreaking approaches to understanding neurological diseases have brought about advances in the broader pharmaceutical industry.
Over the course of his career, Dr. Schenk inspired and mentored dozens of scientists, and his approach to research and development was characterized by creativity, collaboration, and determination. Under his leadership at Prothena, the Company has advanced a new class of protein immunotherapies that seek to fight devastating diseases including AL amyloidosis and Parkinson`s disease. Prior to founding Prothena, Dr. Schenk was executive vice president and chief scientific officer of Elan. Notably, he was the lead researcher on Elan`s experimental vaccine designed to fight Alzheimer`s, with groundbreaking work that earned him the coveted Potamkin Prize from the American Academy of Neurology (AAN). When he won the award, it was the first time that the honor had been bestowed on an industry scientist.
DALE SCHENK - ROCK STAR OF SCIENCE (Click for Rock Star Picture)
Recent AEMD News
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
- Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 11/14/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:01:36 PM
- Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer • PR Newswire (US) • 11/13/2023 01:01:00 PM
- Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023 • PR Newswire (US) • 11/06/2023 01:01:00 PM
- Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology • PR Newswire (US) • 10/10/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 09:05:12 PM
- Aethlon Announces Reverse Stock Split • PR Newswire (US) • 10/04/2023 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:57:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:56:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:54:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 01:00:08 PM
- Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference • PR Newswire (US) • 08/30/2023 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:20:32 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM